J.P. Morgan analyst Anupam Rama has maintained their bullish stance on ANAB stock, giving a Buy rating today.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Anupam Rama has given his Buy rating due to a combination of factors tied to AnaptysBio’s advancing pipeline and structural changes. He views the planned separation into a royalties-focused entity and a biopharma vehicle, including the launch of First Tracks Biotherapeutics in the second quarter of 2026, as a key value-unlocking step that remains on schedule.
He also highlights clinical momentum, notably the continued enrollment of ANB033 in celiac disease with pivotal phase 1b data expected in the fourth quarter of 2026 and a new phase 1b study in eosinophilic esophagitis targeting readout in 2027. In addition, management’s intention to move rosnilimab forward in rheumatoid arthritis using external capital supports his constructive view, leading him to reiterate an Overweight stance on ANAB shares.
In another report released today, TipRanks – Google also upgraded the stock to a Buy with a $58.00 price target.
Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ANAB in relation to earlier this year.